IMNR - Immune Response Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: George C. Grasser who wrote (59)	4/23/1997 1:06:00 AM
From: Mark B. Martell, CCM	of 1510

George, I believe that they are banking on Remune to bring in some revenue soon. The capitalization with the infusion of new cash helps to keep the company profitable until this compound can be proven successful. It appears to me that Remune has the possibility of becoming a significant player in the fight against AIDS, attacking it in an immunization approach. Merck and Glaxo appear to be co-marketers, so they are in good company here. My guess is that they are trying to rush this product through Phase III to market somehow. Their own press release noted that Dr. Gallo of the NIH is behind this effort to increase chemokine production, which Remune is proving to do. Should be an interesting play over the next month or two. Given the terms of the new capitalization, it appears that a bet is being made that the price of the stock will double or triple within a few days/months/year?, or these guys will be paying some significant loan interest. I'd say that they are banking on Remune's success, since their other compounds are further away from entering the market. Just a wild hunch here. Mark

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next